ICU Medical (NASDAQ:ICUI) Stock Price Target Raised at Piper Sandler

ICU Medical (NASDAQ:ICUI) had its price target upped by Piper Sandler from $195.00 to $200.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an “overweight” rating on the medical instruments supplier’s stock. Piper Sandler‘s target price suggests a potential upside of 19.30% from the company’s current price.

A number of other brokerages have also recently issued reports on ICUI. Raymond James Financial reissued a “strong-buy” rating and set a $200.00 target price on shares of ICU Medical in a report on Friday, August 7th. Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Needham & Company LLC lifted their price target on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research report on Friday, August 7th. KeyCorp boosted their price objective on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Finally, BTIG Research boosted their price objective on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $193.80.

ICU Medical Price Performance

NASDAQ ICUI opened at $167.65 on Friday. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. The company has a market cap of $4.19 billion, a PE ratio of 142.08, a price-to-earnings-growth ratio of 2.17 and a beta of 0.88. ICU Medical has a 52 week low of $113.37 and a 52 week high of $192.85. The firm’s 50-day simple moving average is $162.97 and its two-hundred day simple moving average is $149.18.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.30. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm had revenue of $556.22 million during the quarter, compared to the consensus estimate of $552.03 million. During the same quarter last year, the company earned $2.03 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Research analysts predict that ICU Medical will post 7.22 earnings per share for the current year.

Insider Activity

In other news, Director Elisha Finney sold 378 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total value of $68,977.44. Following the transaction, the director owned 4,871 shares of the company’s stock, valued at approximately $888,860.08. This represents a 7.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ben Sousa sold 2,250 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total value of $401,220.00. Following the completion of the sale, the insider owned 3,076 shares in the company, valued at $548,512.32. This trade represents a 42.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 21,830 shares of company stock worth $3,905,003. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ICUI. BlackRock Inc. bought a new position in shares of ICU Medical in the second quarter worth approximately $550,250,000. Jupiter Topco LLC bought a new stake in ICU Medical during the second quarter valued at approximately $407,786,000. Janus Henderson Group PLC lifted its position in ICU Medical by 3.9% during the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock valued at $345,607,000 after purchasing an additional 99,256 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in ICU Medical by 6.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier’s stock worth $127,053,000 after buying an additional 63,026 shares in the last quarter. Finally, Bank of America Corp DE purchased a new position in ICU Medical in the 2nd quarter worth approximately $54,059,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Key Stories Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: ICU Medical reported third-quarter earnings of $2.44 per share, above the $2.14 consensus estimate and up from $2.03 a year earlier. Revenue was $556.22 million, also ahead of expectations, and increased 4.4% year over year. ICU Medical Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: The company reaffirmed fiscal 2026 guidance and said it expects results toward the high end of its previously provided range, signaling confidence in its outlook. ICU Medical Announces Q3 Results and Reaffirms Guidance
• Neutral Sentiment: Despite the earnings beat and reaffirmed guidance, the stock is lower. The articles provided do not point to a clear company-specific reason for the move. ICU Medical Q3 Adjusted Earnings, Revenue Rise

About ICU Medical

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.